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ostic biomarker of acute liver injury in patients with hepatitis
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Background: Hepatitis E virus (HEV)infectionis endemic in
ndia. The disease manifestation ranges fromasymptomatic infec-
ion to acute viral hepatitis (AVH) and acute liver failure (ALF). The
athogenesis of Hepatitis E is poorly understood. High mobility
roup box 1 (HMGB-I) is a non-histone chromosomal protein with
ecently discovered proinﬂamatory and immunomodulatory effect
n sepsis. Hypothesizing the damage in HEV is immune mediated;
he present study was designed to elucidate the role of circulat-
ng HMGB1 in serum and its gene expression in peripheral blood
ono-nuclear cells (PBMCs).
Methods: Approximately 10 ml of venous blood was collected
rom 47 HEV patients (33 AVH and 14 ALF), conﬁrmed by anti-
EV IgM and/or HEV RNA positivity. The control group (n= 20)
omprised of age and sex matched apparently healthy volun-
eers. Serum was separated and PBMCs were isolated using Ficoll.
pproximately 2x105PBMCs/wellwere cultured inRPMI-1640and
ulsedwith recombinantHEVORF2protein (452-617a.a). Routine
iochemical investigations were performed and levels of circulat-
ng HMGB1 were estimated by quantitative micro ELISA. Gene
xpression levels in the patient PBMCs were checked using Real
ime RT- PCR. Lymphocyte proliferation was estimated using Col-
rimetric MTT assay.
Results: Mean circulating HMGB1 levels in healthy controls
HC), AVH and ALF patient groups were found to be 18.29±16.68
g/ml, 155.4±89.51 ng/ml and 306±70.38 ng/ml respectively. The
LF patients had signiﬁcantly higher levels than AVH patients
p<0.0001). Interestingly 90% of the patients who succumbed to
isease, had circulating HMGB1 levels > 250 ng/ml. However the
ene expression in the PBMCs between ALF and AVH patients in
omparison to HC were upregulated to 2.5 and 2.0 folds respec-
ively. A signiﬁcantly low proliferation index was observed in ALF
2.188±0.722) Vs AVH (3.040±0.667) patients (p=0.008). Strong
egative correlation was found between the HMGB1 levels and
rothrombin time index (PTI) in the ALF patients.
Conclusion: This suggests, massive destruction of hepatocytes
ight lead to excessive accumulation of extracellular HMGB1
hich downregulates T cell proliferation. Thus, excessive circulat-
ng HMGB1 protein might play a key role in ALF patients towards
mmunosupression and fulminant disease course following HEV
nfection.
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Background: Chronic infection with Hepatitis B virus (HBV) is
a global health problem, with over 350 million carriers worldwide
and up to 1,000,000 deaths annually from HBV-associated cirrho-
sis or hepatocellular carcinoma. There is signiﬁcant unmet medical
need for new treatments yielding a clinical cure or disease suppres-
sion with limited dosing and limited adverse effects.
RNA interference (RNAi) is a promising modality for the treat-
ment of viral disease. RNAi trigger molecules, such as small
interfering RNAs (siRNAs), can be readily designed to possess the
speciﬁcity, potency, andﬂexibility to target anyviral genewithhigh
efﬁcacy and without the side effects observed with existing anti-
viral drugs. The challenge in using anti-HBV siRNAs as drugs is to
safely and effectively deliver them to hepatocytes. To this end, we
developed an siRNA delivery vehicle named Dynamic PolyConju-
gates (DPCs).
Methods: 145 anti-HBV siRNAs designed to target conserved
sequences in HBV serotypes A-D were synthesized and then
screened in cultured cells to identify thosewith highest potency. To
determineefﬁcacy in vivo, lead siRNAswere formulated inDPCsand
intravenously injected in mouse models of HBV infection. Studies
to assess toxicity were conducted in rats and non-human primates
(NHPs).
Results: Four biweekly injections of anti-HBV siRNA DPCs in
mice carrying a hepatocyte-speciﬁc reporter gene fused to HBV
sequences resulted in a 3-4 log reduction in gene expression over
2 months without changes in cytokines or clinical chemistries. Sin-
gle dose injections in a replication-competent, transient transgenic
HBV mouse model resulted in greatly reduced serum HBsAg lev-
els (> 2 logs) and serum levels of HBV DNA. Single dose studies
using transgenic HBV mice revealed dramatic reductions in HBeAg
levels in serum, and in viral RNAs and viral replication intermedi-
ates in the liver. Safety and tolerability studies using rats and NHPs
revealed that DPCs have a wide safety margin.
Conclusion: Formulation of potent anti-HBV siRNAs in DPCs
allowed highly effective reduction of viral protein production and
viral load in mouse models of HBV infection. Combined with the
favorable results observed in toxicological studies, we anticipate
that anti-HBV siRNA DPCs will become a viable therapeutic for
patients with chronic HBV infection.
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